Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Baird raises Crinetics shares target citing promising drug results

EditorEmilio Ghigini
Published 2024-05-23, 06:56 a/m
© Reuters.
CRNX
-

On Thursday, Baird raised the price target on Crinetics Pharmaceuticals (NASDAQ: NASDAQ:CRNX) shares from $52 to $62, while maintaining an Outperform rating.

The adjustment follows the early release of abstracts related to the company's drug atumelnant, which is under development for the treatment of congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

The abstracts revealed that atumelnant led to fast and significant reductions in critical biomarkers for both conditions. Specifically, the drug showed a reduction in A4 for CAH and cortisol levels for Cushing's syndrome. These promising results have led to increased optimism about the drug's potential efficacy.

Baird's analyst highlighted the significance of the findings, noting that the data suggests a very high probability of success for atumelnant. The diseases' biology is well-understood, and the recent results align with this knowledge, strengthening confidence in the drug's development.

Despite the anticipation of a multi-year development plan before potential approval, the analyst believes the compelling results justify the raised price target. The new target reflects the positive outlook for atumelnant based on the recent findings.

Crinetics Pharmaceuticals is engaged in the development of atumelnant as a treatment option for patients with CAH and Cushing's syndrome, conditions that currently have limited therapeutic options. The company's progress in these areas is closely watched by investors and the medical community alike.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.